As shown in Table 2, PTX-specific AEs, such as sensory neuropathy, arthralgia, myalgia, and liver dysfunction occurred at a high frequency, whereas nab-PTX was stably administered in combination with anti-HER2 therapy by controlling the appropriate supportive care, leading to preferred clinical outcome [13, 18, 19]. The gene discussed is ERBB2; the disease is sensory peripheral neuropathy.